fda compounding semaglutide news today Popular diabetes drug is a 'good story.' Here's why consumers need to proceed with caution FDA Warns on Certain Forms

MSDC-0602K has shown substantial decreases in glucose, insulin, liver enzymes, and the non-alcoholic fatty liver disease activity score (NAS) in patients with biopsy-confirmed MASH and fibrosis (F1-F3) with minimal side effects, 21 prompting a phase 3 study to assess the benefits of MSDC-0602K on glycemic control and cardiovascular outcomes in patients with pre-T2D or T2D and MASLD/MASH (NCT03970031)

A leading biotechnology company recently presented interim Phase II results of its anti-myostatin and anti-activin monoclonal antibodies in combination with a GLP-1 that preserved lean mass by 50%-80% with contingent weight loss

the compound delivered clinically meaningful improvement in glycemic control and body weight warranting further clinical evaluation for the treatment of T2DM and obesity [21]

Why Choose Direct Health Shop

Laboratory testing to evaluate metabolic health markers, hormonal status, and nutritional parameters 4

Testing: Third-party lab report available where provided